Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Bonsai Partners. This analysis is provided for institutional research purposes only and is not investment advice.
"Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Molson Coors."
Bonsai Partners Fund, LP returned 7.3% net of fees and expenses for the first six months of 2025, outperforming the S&P 500's 6.2% return. The letter details the manager's core 'Enduring Economics' framework—highlighting Wise plc as a prime example—and features an extensive write-up on Fever-Tree Drinks (FEVR.L). The manager explains that Fever-Tree's past margin challenges (caused by shipping European-made products across the Atlantic) are solved by its new exclusive partnership with Molson Coors. This deal transitions Fever-Tree's U.S. operations to an asset-light royalty model with guaranteed minimum payments, significantly improving visibility for earnings growth.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Growth Outlook
Market outlook remains above average conviction: Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Risk Appetite
Risk appetite posture is above average conviction: Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Forward Guidance
Forward guidance signal: Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Language Signal
Tone analysis indicates high conviction language: Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
Time Horizon
Investment time horizon reflects a high conviction orientation. Bonsai Partners appreciated 7.3% net in H1 2025, outperforming the S&P 500, and significantly increased its stake in Fever-Tree following a transformative U.S. partnership with Mol...
